These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27846724)

  • 21. Prospects for targeting PD-1 and PD-L1 in various tumor types.
    Kim JW; Eder JP
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.
    Muenst S; Soysal SD; Tzankov A; Hoeller S
    Expert Opin Ther Targets; 2015 Feb; 19(2):201-11. PubMed ID: 25491730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.
    Baban B; Liu JY; Qin X; Weintraub NL; Mozaffari MS
    PLoS One; 2015; 10(4):e0124059. PubMed ID: 25902191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].
    Obermannova R
    Klin Onkol; 2017; 30(Supplementum3):50-54. PubMed ID: 29239193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
    Sui X; Ma J; Han W; Wang X; Fang Y; Li D; Pan H; Zhang L
    Oncotarget; 2015 Aug; 6(23):19393-404. PubMed ID: 26305724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic and predictive markers for the new immunotherapies.
    Mahoney KM; Atkins MB
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
    Chen DS; Irving BA; Hodi FS
    Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].
    Shi MH; Xing YF; Zhang ZL; Huang JA; Chen YJ
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):85-8. PubMed ID: 23714659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
    Ansell SM
    J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.
    Poulet FM; Wolf JJ; Herzyk DJ; DeGeorge JJ
    Birth Defects Res B Dev Reprod Toxicol; 2016 Apr; 107(2):108-19. PubMed ID: 27062127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.
    Zandberg DP; Strome SE
    Oral Oncol; 2014 Jul; 50(7):627-32. PubMed ID: 24819861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Insight into the Role of the PD-1/PD-L1 Pathway in Feto-Maternal Tolerance and Pregnancy.
    Zhang YH; Tian M; Tang MX; Liu ZZ; Liao AH
    Am J Reprod Immunol; 2015 Sep; 74(3):201-8. PubMed ID: 25640631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.
    Ji M; Liu Y; Li Q; Li XD; Zhao WQ; Zhang H; Zhang X; Jiang JT; Wu CP
    J Transl Med; 2015 Jan; 13():5. PubMed ID: 25592115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Dancing Couple: PD-L1 and MicroRNA.
    Grenda A; Krawczyk P
    Scand J Immunol; 2017 Sep; 86(3):130-134. PubMed ID: 28675453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.